Apellis Pharmaceuticals, Inc. (APLS)
May 14, 2026 - APLS was delisted (reason: acquired by BIIB)
41.03
-0.03 (-0.07%)
Inactive · Last trade price on May 13, 2026

Revenue

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
EMPAVELI Revenue
124.01M102.45M98.09M
EMPAVELI Revenue Growth
21.05%4.44%7.75%
SYFOVRE Revenue
607.48M586.93M611.86M
SYFOVRE Revenue Growth
3.50%-4.07%122.30%
Total Product Revenue
731.49M689.38M709.95M
Total Product Revenue Growth
6.11%-2.90%93.83%
Licensing and Other Revenue
373.79M314.40M71.41M
Licensing and Other Revenue Growth
18.89%340.25%135.61%
Revenue (Other)
--2.00K-
Revenue (Total)
1.11B1.00B781.37M
Revenue (Total) Growth
10.11%28.46%97.02%
Updated May 7, 2026. Data Source: Fiscal.ai.